Financing Highlights Focus

• Small molecule drugs run neck and neck with cell and gene therapies (CGT):More than 10 companies have clearly laid out small molecule drug pipelines, such as GuangZhou GaoLing Pharmaceutical Company,Ltd.Sansheng Pharmaceutical, Muda Biotechnology, etc.The advantages lie in the convenience of oral administration, relatively mature development pathways, and flexibility in modulating complex CNS targets. More than 10 companies, such as RefGene Biotech, Ruizhen Regenerative Medicine, and Ruijian Pharmaceuticals, are also involved in the CGT field. CGT offers the potential for curative therapies and targeting traditionally "undruggable" targets.

• Innovation in Drug Delivery Technology Broadens Treatment Boundaries: 6These companies focus on key research in drug delivery technologies, including Rona Therapeutics' extrahepatic siRNA delivery platform, MicroLight Gene’s gene editing vector optimization, and NewLife Pharma’s nasal spray., focusing on solving the blood-brain barrier penetration challenges in CNS drug development.

• AI Deeply Empowers the Entire Chain of Drug Research and Development:5HomeThe company clearly identifies artificial intelligence as a key technology, applied in target discovery (such as SanSheng Pharmaceuticals'AI Assistant Drug Discovery Platform), molecular design (e.g., Insilico IntelligenceChemistry42 Platform), cell induction (such as Ru Jian Pharmaceutical's "AI + chemical induction" platform), and other processes, significantly improving R&D efficiency.

GuangZhou GaoLing Pharmaceutical Company,Ltd.:Innovative Drug Research and Development Company for Immune and Inflammatory Diseases

On January 3, GuangZhou GaoLing Pharmaceutical Company, Ltd. announced the completion of a Pre-C round of financing worth 150 million RMB.

GaoGuang Pharmaceuticals is an innovative drug development company focused on researching and developing small-molecule drugs for autoimmune and inflammatory diseases, as well as neurodegenerative disorders.GuangZhou GaoLing Pharmaceutical Company, Ltd.Built multiple early pipelines targeting neuroinflammation/central nervous system diseases, including the TYK2/JAK1 dual inhibitor TLL041 with blood-brain barrier penetration properties., intended for the treatment of Alzheimer's disease and Parkinson's disease. In 2023, Biohaven entered into a collaboration worth approximately $970 million with GuangZhou GaoLing Pharmaceutical Company, Ltd., securing the exclusive development and licensing rights for TLL-041 outside of Greater China.

Rona Therapeutics:siRNA Drug Development Company

March 14, Rona Therapeutics（Rona Therapeutics）Rona Therapeutics Announces Completion of Pre-B Round Financing, Raising $25 Million. This financing will help Rona Therapeutics advance its proprietary delivery and chemical modification platform technology, further expanding its siRNA clinical pipeline in cardiovascular metabolism, weight loss, and other fields.

Rona Therapeutics was founded in 2021,Rona Therapeutics is a nucleic acid innovative drug platform company that focuses on the treatment of metabolic diseases and central nervous system degenerative diseases. Among them,Rona Therapeutics focuses onCentral Nervous System Degenerative Diseases Field, deeply exploring the potential of extrahepatic nucleic acid delivery, successfully established a unique extrahepatic delivery platform. This platform exhibits strong knockdown efficiency and remarkable longevity, enabling a dosing cycle of up to nine months or longer. Currently, multiple extrahepatic delivery pipeline products have entered the preparation stage for new drug clinical research applications, aiming to treat a series of complex diseases such as amyotrophic lateral sclerosis and Alzheimer's disease, which are challenging to address with traditional drug therapies.

NeuShen Therapeutics:Pharmaceutical R&D Company for Mental and Nervous System Diseases

In April, NeuShen Therapeutics completed an A-round financing of tens of millions of US dollars.This round of financing will be used to advance the clinical development of NeuShen Pharma's core R&D projects, including those that have completed Phase 1 clinical trials.NS-041 for multiple indications including epilepsy, mood disorders, and pain(Selective KCNQ2/3 channel agonist) project andNS-136 for the treatment of agitation symptoms associated with schizophrenia and Alzheimer's disease等老年痴呆(M4 muscarinic acetylcholine receptor positive allosteric modulator) project, as well as advancing the IND development for multiple projects targeting treatment-resistant depression, Alzheimer's disease, and Parkinson's disease.

NeuShen Therapeutics is a clinical-stage biotechnology company,Focus on Developing Innovative Therapies for Neurological and Psychiatric DisordersThe company's innovative drug pipeline has seen multiple advancements, with the core product NS-041 recently completing Phase 1 clinical trials: the drug has maintained excellent safety and tolerability characteristics and demonstrated a superior therapeutic index, providing data support for its subsequent clinical development. Currently, the drug has progressed to the Phase 2 Proof-of-Concept study stage for focal epilepsy and is simultaneously initiating indication expansion targeting significant unmet clinical needs such as mood disorders and neuropathic pain.

 Ru Jian Pharmaceutical:Stem Cell Therapy R&D Company

News on April 11, Rona Therapeutics announced the completionNearly 100 Million Yuan in B+ Round Financing. According to the press release,Following the completion of an over 100 million yuan Series B financing round in October last year, Rona Therapeutics has cumulatively raised more than 200 million yuan in less than half a year.The funds from this round of financing will be used forAccelerate the Advancement of Rona Therapeutics' Parkinson's Disease Treatment Products NouvNeu001/NouvNeu003, as well as the advancement of the ophthalmic treatment product NouvSight001 in clinical trials in China and the United States, strengthening the company's R&D progress of multiple innovative pipelines and the establishment of clinical capabilities, etc.

Rona Therapeutics was founded in 2017 as an innovative biopharmaceutical company focused on the field of regenerative medicine. Through its unique technology platform, the company specializes in small molecule chemical transcriptional regulation to induce pluripotent stem cells (iPSC), thereby developing universal chemically induced cell therapy drugs. NouvNeu001 injection, a chemically induced functional human dopaminergic neuron precursor cell developed by Rona Therapeutics, received approval from China's NMPA in August 2023 to commence combined Phase 1-2 clinical research. Based on positive Phase 1 data, Rona Therapeutics is expected to officially launch Phase 2 clinical trials in the near future.

Anranfei:Neurotransmitter Secretion Regulation Drug Development Company

News on April 17th, Anranfi announced the completion of an angel round of financing worth tens of millions of yuan. The funds from this round will be mainly used forR&D Pipeline for Innovative Drugs Targeting Neurological Disorders Represented by Parkinson's Disease。

Anranfei was founded in 2023, dedicated to the research and development of innovative drugs that regulate neurotransmitter secretion. The company's founder, Dr. Zhang Yanfeng, has over fifteen years of research experience in dopamine secretion and function. Anranfei’s innovative platform modulates the efficiency of converting electrical signals to chemical signals in nerve cells, enabling endogenous regulation of neurotransmitter secretion without affecting the firing frequency of neurons—thus preserving their physiological significance. This allows for direct physiological control of targeted neurotransmitter secretion for treating various diseases. The company’s first innovative drug pipeline targets Parkinson’s disease, achieving direct modulation of dopaminergic neuron secretion through a novel target. Once developed into a drug, it has the potential to treat Parkinson’s disease independently (without relying on levodopa). Preclinical study data shows that its standalone treatment significantly increases dopamine secretion, with all treated Parkinson’s model mice regaining motor function.

Readers, please star ⭐Chuangjianhui to receive updates第一时间收到推送.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share to Moments, Unauthorized media or institutions are prohibited to reprint/copy in any form to other platforms. For reprint authorization, please contact"Chuang Jian Hui"Contact us via the WeChat Official Account.

More Data Content Recommended

Click "InSee", Sharing Chuangjian Hui Health New Dynamics